{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:00:18Z","timestamp":1789074018630,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Research and Development Plan Project of Jining City in 2024","award":["2024YXNS232"],"award-info":[{"award-number":["2024YXNS232"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men worldwide, with metastatic castration-resistant prostate cancer (mCRPC) presenting a particularly formidable therapeutic challenge. The limited efficacy of conventional immunotherapies targeting the PD-1\/PD-L1 axis in PCa has spurred intensive research into alternative immune checkpoints. Among the B7 family of immunomodulatory proteins, B7-H3 (CD276) and B7-H4 (VTCN1\/B7x\/B7S1) have emerged as critical regulators of PCa pathogenesis, progression, and therapeutic resistance. This comprehensive review synthesizes current evidence from preclinical and clinical studies to delineate the multifaceted roles of B7-H3 and B7-H4 in PCa. We first detail the expression patterns of these molecules in PCa tissues and their robust correlation with adverse clinicopathological features, including high Gleason score, advanced tumor stage, metastasis, and poor survival outcomes. We then explore the complex molecular mechanisms underlying their pro-tumorigenic functions, encompassing immune suppression (inhibition of T-cell activity, modulation of myeloid-derived suppressor cells [MDSCs] and tumor-associated macrophages [TAMs]) and non-immune effects (regulation of cancer stem cells [CSCs], DNA damage repair [DDR], androgen receptor [AR] signaling, and tumor dormancy). Furthermore, we systematically review the rapidly expanding landscape of therapeutic strategies targeting B7-H3 and B7-H4, including antibody\u2013drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, monoclonal antibodies, bispecific agents, and combination therapies with radiotherapy, AR pathway inhibitors (ARPIs), or other immunotherapies. We also discuss emerging directions such as liquid biopsy for B7-H3 detection, B7-H4-targeted immunoPET imaging, racial disparities in B7-H3 expression, and the development of predictive biomarkers for treatment response. Collectively, this review establishes B7-H3 and B7-H4 as pivotal nodes in PCa biology and highlights\u00a0their promising potential to improve\u00a0the clinical management of advanced and treatment-resistant PCa through improved prognostic stratification and the development of novel precision therapies.<\/jats:p>","DOI":"10.1007\/s12672-026-04926-0","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T17:16:32Z","timestamp":1776618992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic and therapeutic roles of B7-H3 and B7-H4 in prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Yunxi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"4926_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4926_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.","journal-title":"Front Public Health"},{"key":"4926_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378:645\u201357.","journal-title":"N Engl J Med"},{"key":"4926_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"12","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;12:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"4926_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700\u201312.","journal-title":"Lancet Oncol"},{"key":"4926_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","volume":"20","author":"JS de Bono","year":"2020","unstructured":"de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20:455\u201369.","journal-title":"Nat Rev Cancer"},{"key":"4926_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","volume":"20","author":"BM Carreno","year":"2002","unstructured":"Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002;20:29\u201353.","journal-title":"Annu Rev Immunol"},{"key":"4926_CR8","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7\u2013H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22:3425\u201331.","journal-title":"Clin Cancer Res"},{"key":"4926_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.yexcr.2005.01.018","volume":"306","author":"S Salceda","year":"2005","unstructured":"Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, et al. The immunomodulatory protein B7\u2013H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res. 2005;306:128\u201341.","journal-title":"Exp Cell Res"},{"key":"4926_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7\u2013H3: a costimulatory molecule for T cell activation and IFN-\u03b3 production. Nat Immunol. 2001;2:269\u201374.","journal-title":"Nat Immunol"},{"key":"4926_CR11","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","volume":"173","author":"DV Prasad","year":"2004","unstructured":"Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, et al. Murine B7\u2013H3 is a negative regulator of T cells. J Immunol. 2004;173:2500\u20136.","journal-title":"J Immunol"},{"key":"4926_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni967","volume":"4","author":"WK Suh","year":"2003","unstructured":"Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4:899\u2013906.","journal-title":"Nat Immunol"},{"key":"4926_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur Urol. 2023;83:224\u201338.","journal-title":"Eur Urol"},{"key":"4926_CR14","doi-asserted-by":"publisher","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","volume":"67","author":"TJ Roth","year":"2007","unstructured":"Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67:7893\u2013900.","journal-title":"Cancer Res"},{"key":"4926_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1074-7613(03)00152-3","volume":"18","author":"GL Sica","year":"2003","unstructured":"Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18:849\u201361.","journal-title":"Immunity"},{"key":"4926_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1074-7613(03)00147-X","volume":"18","author":"DV Prasad","year":"2003","unstructured":"Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003;18:863\u201373.","journal-title":"Immunity"},{"key":"4926_CR17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5c00637","volume":"22","author":"M Kumar","year":"2025","unstructured":"Kumar M, Singh SB, Vasyliv I, Habte F, Kalita M, Alam IS, et al. B7-H4 ImmunoPET imaging tracks tumor-associated macrophage changes in prostate cancer. Mol Pharmaceutics. 2025;22:22.","journal-title":"Mol Pharmaceutics"},{"key":"4926_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1158\/1541-7786.MCR-24-0958","volume":"23","author":"N Kang","year":"2025","unstructured":"Kang N, Xue H, Wong NKY, Lin YY, Classen A, Wu R, et al. Exploring B7-H4\u2019s role in prostate cancer dormancy post-androgen deprivation therapy: extracellular matrix interactions and therapeutic opportunities. Mol Cancer Res. 2025;23:327\u201338.","journal-title":"Mol Cancer Res"},{"key":"4926_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/pin.12999","volume":"70","author":"S Bonk","year":"2020","unstructured":"Bonk S, Tasdelen P, Kluth M, Hube-Magg C, Makrypidi-Fraune G, M\u00f6ller K, et al. High B7-H3 expression is linked to increased risk of prostate cancer progression. Pathol Int. 2020;70:743\u201352.","journal-title":"Pathol Int"},{"key":"4926_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6732","volume":"15","author":"Y Yamada","year":"2023","unstructured":"Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM, et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 2023;15:eadf6732.","journal-title":"Sci Transl Med"},{"key":"4926_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.trecan.2024.05.003","volume":"10","author":"R Pulido","year":"2024","unstructured":"Pulido R, L\u00f3pez JI, Nunes-Xavier CE. B7-H3: a robust target for immunotherapy in prostate cancer. Trends Cancer. 2024;10:584\u20137.","journal-title":"Trends Cancer"},{"key":"4926_CR22","doi-asserted-by":"publisher","first-page":"19458","DOI":"10.1073\/pnas.0709802104","volume":"104","author":"X Zang","year":"2007","unstructured":"Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104:19458\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4926_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41391-021-00331-6","volume":"24","author":"G Amori","year":"2021","unstructured":"Amori G, Sugawara E, Shigematsu Y, Akiya M, Kunieda J, Yuasa T, et al. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:767\u201374.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4926_CR24","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3748\/wjg.v21.i6.1804","volume":"21","author":"T Zhang","year":"2015","unstructured":"Zhang T, Jiang B, Zou SJ, Liu F, Hua D. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3. World J Gastroenterol. 2015;21:1804\u201313.","journal-title":"World J Gastroenterol"},{"key":"4926_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, He L, Sadagopan A, Ma T, Dotti G, Wang Y, et al. Targeting radiation-resistant prostate cancer stem cells by B7\u2013H3 CAR T cells. Mol Cancer Ther. 2021;20:577\u201388.","journal-title":"Mol Cancer Ther"},{"key":"4926_CR26","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1002\/cncr.34190","volume":"128","author":"AA Mendes","year":"2022","unstructured":"Mendes AA, Lu J, Kaur HB, Zheng SL, Xu J, Hicks J, et al. Association of B7\u2013H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer. 2022;128:2165\u201376.","journal-title":"Cancer"},{"key":"4926_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101207","volume":"79","author":"Y Ju","year":"2025","unstructured":"Ju Y, Watson J, Wang JJ, Yen YT, Gevorkian L, Chen Z, et al. B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer. Drug Resist Updates. 2025;79:101207.","journal-title":"Drug Resist Updates"},{"key":"4926_CR28","doi-asserted-by":"publisher","first-page":"29480","DOI":"10.18632\/oncotarget.8784","volume":"7","author":"J Ma","year":"2016","unstructured":"Ma J, Ma P, Zhao C, Xue X, Han H, Liu C, et al. B7\u2013H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget. 2016;7:29480\u201391.","journal-title":"Oncotarget"},{"key":"4926_CR29","doi-asserted-by":"publisher","first-page":"153303382097164","DOI":"10.1177\/1533033820971649","volume":"19","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang G, Zhang W, Wei X, Hou J, Huang Y. B7\u2013H3 promotes prostate cancer progression in mice by antagonizing myeloid-derived suppressor cell apoptosis. Technol Cancer Res Treat. 2020;19:1533033820971649.","journal-title":"Technol Cancer Res Treat"},{"key":"4926_CR30","doi-asserted-by":"publisher","first-page":"12640","DOI":"10.1073\/pnas.0405025101","volume":"101","author":"R Castriconi","year":"2004","unstructured":"Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A. 2004;101:12640\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4926_CR31","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.3892\/mmr.2015.4050","volume":"12","author":"F Liu","year":"2015","unstructured":"Liu F, Zhang T, Zou S, Jiang B, Hua D. B7H3 promotes cell migration and invasion through the Jak2\/Stat3\/MMP9 signaling pathway in colorectal cancer. Mol Med Rep. 2015;12:5455\u201360.","journal-title":"Mol Med Rep"},{"key":"4926_CR32","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.7150\/ijbs.41105","volume":"16","author":"S Yang","year":"2020","unstructured":"Yang S, Wei W, Zhao Q. B7\u2013H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16:1767\u201373.","journal-title":"Int J Biol Sci"},{"key":"4926_CR33","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-15-1538","volume":"76","author":"S Lim","year":"2016","unstructured":"Lim S, Liu H, Madeira da Silva L, Arora R, Liu Z, Phillips JB, et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1\u03b1. Cancer Res. 2016;76:2231\u201342.","journal-title":"Cancer Res"},{"key":"4926_CR34","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s41417-023-00644-9","volume":"30","author":"N Kang","year":"2023","unstructured":"Kang N, Xue H, Lin YY, Dong X, Classen A, Wu R, et al. Influence of ADT on B7\u2013H3 expression during CRPC progression from hormone-na\u00efve prostate cancer. Cancer Gene Ther. 2023;30:1382\u20139.","journal-title":"Cancer Gene Ther"},{"key":"4926_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6724","volume":"15","author":"W Shi","year":"2023","unstructured":"Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023;15:eadf6724.","journal-title":"Sci Transl Med"},{"key":"4926_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.trecan.2024.05.003","volume":"10","author":"R Pulido","year":"2024","unstructured":"Pulido R, L\u00f3pez JI, Nunes-Xavier CE. B7\u2013H3: a robust target for immunotherapy in prostate cancer. Trends Cancer. 2024;10:584\u20137.","journal-title":"Trends Cancer"},{"key":"4926_CR37","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","volume":"19","author":"JA Scribner","year":"2020","unstructured":"Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, et al. Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7\u2013H3 for solid cancer. Mol Cancer Ther. 2020;19:2235\u201344.","journal-title":"Mol Cancer Ther"},{"key":"4926_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","volume":"39","author":"S Jang","year":"2021","unstructured":"Jang S, Powderly J, Spira A, Bakkacha O, Loo D, Bohac G, et al. Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol. 2021;39:2631.","journal-title":"J Clin Oncol"},{"key":"4926_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","volume":"9","author":"S Li","year":"2023","unstructured":"Li S, Zhang M, Wang M, Wang H, Wu H, Mao L, et al. B7\u2013H3 specific CAR-T cells exhibit potent activity against prostate cancer. Cell Death Discov. 2023;9:147.","journal-title":"Cell Death Discov"},{"key":"4926_CR40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","volume":"29","author":"E Shenderov","year":"2023","unstructured":"Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med. 2023;29:888\u201397.","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"4926_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-O8","volume":"3","author":"J Powderly","year":"2015","unstructured":"Powderly J, Cote G, Flaherty K, Szmulewitz RZ, Ribas A, Weber J, et al. Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer. 2015;3(Suppl 2):P232.","journal-title":"J Immunother Cancer"},{"key":"4926_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101232","volume":"14","author":"X Liu","year":"2021","unstructured":"Liu X, Zhelev D, Adams C, Chen C, Mellors JW, Dimitrov DS. Effective killing of cells expressing CD276 (B7\u2013H3) by a bispecific T-cell engager based on a new fully human antibody. Transl Oncol. 2021;14:101232.","journal-title":"Transl Oncol"},{"key":"4926_CR43","first-page":"345","volume":"39","author":"Y Qian","year":"2010","unstructured":"Qian Y, Yao HP, Shen L, Cheng LF, Zhang LH. Expression of B7\u2013H4 in prostate cancer and its clinical significance. J Zhejiang Univ (Med Sci). 2010;39:345\u20139.","journal-title":"J Zhejiang Univ (Med Sci)"},{"key":"4926_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2020.104406","volume":"114","author":"H Li","year":"2020","unstructured":"Li H, Piao L, Liu S, Cui Y, Xuan Y. B7\u2013H4 is a potential prognostic biomarker of prostate cancer. Exp Mol Pathol. 2020;114:104406.","journal-title":"Exp Mol Pathol"},{"issue":"suppl 16","key":"4926_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3008","volume":"40","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Oh D-Y, Naito Y, Shimizu T, Chung V, Park H, et al. First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced\/metastatic solid tumors. J Clin Oncol. 2022;40(suppl 16):3008.","journal-title":"J Clin Oncol"},{"key":"4926_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002455","volume":"9","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Li K, Lai Y, Yao K, Wang Q, Zhan X, et al. B7 score and T cell infiltration stratify immune status in prostate cancer. J Immunother Cancer. 2021;9:e002455.","journal-title":"J Immunother Cancer"},{"key":"4926_CR47","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s00259-024-06714-w","volume":"51","author":"Y Tian","year":"2024","unstructured":"Tian Y, Shen H, Li L, Jia X, Liu J, Hu Z, et al. Enhancing surgical outcomes: accurate identification and removal of prostate cancer with B7-H3-targeted NIR-II molecular imaging. Eur J Nucl Med Mol Imaging. 2024;51:2569\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04926-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:22:49Z","timestamp":1781648569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04926-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4926"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04926-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"822"}}